Opal Wealth Advisors’s Arbutus Biopharma ABUS Stock Holding History

Opal Wealth Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-100	Closed	-$309	–	195
2024 Q2	$309	Buy	+100	New	+$300	﹤0.01%	1199

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FCM

FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Opal Wealth Advisors's ABUS Position: Q3 2024 in Review

Opal Wealth Advisors sold out of Arbutus Biopharma (ABUS) in Q3 2024, closing a stake of 100 shares — an estimated $309 sold.

Opal Wealth Advisors first reported a position in ABUS in Q2 2024 and held it in 1 quarter. The position peaked at $309 in Q2 2024. 144 funds tracked by Wall St. Rank hold ABUS as of Q3 2024.

Opal Wealth Advisors reported no remaining Arbutus Biopharma position as of Q3 2024 after selling out during the quarter.
Opal Wealth Advisors sold 100 Arbutus Biopharma shares in Q3 2024, an estimated $309.
Opal Wealth Advisors first reported a position in Arbutus Biopharma in Q2 2024 and held it in 1 quarter.
Opal Wealth Advisors's Arbutus Biopharma position peaked at $309 in Q2 2024.
144 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2024.

Based on Opal Wealth Advisors's 13F filing for Q3 2024, filed 15 Oct 2024.